New research collaboration to study RNA-binding proteins for the creation of new therapeutic target candidates
Posted: 20 April 2015 | Victoria White
Takeda, Keio University and Niigata University are to collaborate to research disease-related RNA-binding proteins, possibly leading to new treatments…
Just days after announcing their collaboration with CiRA on iPS cell research, Takeda has entered in to another collaborative research agreement with Keio University School of Medicine and Niigata University regarding the search for and functional analysis of disease-related RNA-binding proteins.
This may lead to treatments in the areas such as CNS and oncology.
This collaboration is scheduled to last three years, with Professor Hideyuki Okano of the Physiology Laboratory at Keio University School of Medicine directing the overall research, with Associate Professor Masato Yano from Niigata University participating as well.
Biomarkers are redefining how precision therapies are discovered, validated and delivered.
This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Inside the report:
- How leading organisations are reshaping strategy with biomarker-led approaches
- Better tools for real-time decision-making – turning complex data into faster insights
- Global standardisation and assay sensitivity – what it takes to scale across networks
Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today
Research collaboration will focus on the systematic and comprehensive study of RNA-binding proteins
The relationship between disease pathology and RNA-binding proteins has gradually become clearer in recent years, and a diseases’ onset and progression is now thought to be linked to abnormalities in RNA-binding proteins. This research collaboration will focus on the systematic and comprehensive study of RNA-binding proteins, with the aim of creating new therapeutic target candidates and game-changing technologies for drug discovery.
“We hope to produce innovative results for drug discovery through the uniting of our research on RNA-binding proteins with Takeda’s science technology platform,” said Professor Hideyuki Okano, Keio University School of Medicine.
By collaborating with both universities, Takeda hopes to create ground-breaking medicine
“I am very excited to welcome Professor Okano, who is one of the world’s leading researchers engaged in RNA-binding proteins, into this important Initiative,” said Tetsuyuki Maruyama, General Manager of the Pharmaceutical Research Division. “By collaboration with both universities, Takeda hopes to create the new ground-breaking medicine that patients are waiting for.”
For more information about Takeda Pharmaceutical Company Ltd., please visit www.takeda.com.
Related topics
Drug Discovery, RNAs
